The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Clinical practice guidelines for the management of adult diffuse gliomas
Abstract
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationAn extent of resection threshold for newly diagnosed glioblastomas: Clinical article
Sanai, N., Polley, M.-Y., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,646
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., Kleinschmidt-DeMasters, B. K., Perry, A., Reifenberger, G., Stupp, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1913-0 · Cited by 896
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
McGirt, M. J., Chaichana, K. L., Gathinji, M., Attenello, F. J., Than, K., Olivi, A., Weingart, J. D., Brem, H., & Quiñones-Hinojosa, A. R. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17536 · Cited by 809
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Clonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720
Self-citationPatel, A. P., Fisher, J. L., Nichols, E., Abd-Allah, F., Abdela, J., Abdelalim, A., Abraha, H. N., Agius, D., Alahdab, F., Alam, T., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30468-x · Cited by 647
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Self-citationEZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535
Louis, D. N., Wesseling, P., Aldape, K., Brat, D. J., Capper, D., Cree, I. A., Eberhart, C., Figarella‐Branger, D., Fouladi, M., Fuller, G. N., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12832 · Cited by 525
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figrarella-Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 520
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445
Response Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Bao, Z.-S., Chen, H.-M., Yang, M.-Y., Zhang, C.-B., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 409
Self-citationLombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
Louis, D. N., Giannini, C., Capper, D., Paulus, W., Figarella-Branger, D., Lopes, M. B., Batchelor, T. T., Cairncross, J. G., van den Bent, M., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1826-y · Cited by 396
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
Hu, H., Mu, Q., Bao, Z., Chen, Y., Liu, Y., Chen, J., Wang, K., Wang, Z., Nam, Y., Jiang, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.038 · Cited by 345
Self-citationWijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Smits, M., Gahrmann, R., Rutten, G.-J., Verheul, J. B., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox176 · Cited by 334
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 324
Pekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319
Stichel, D., Ebrahimi, A., Reuss, D., Schrimpf, D., Ono, T., Shirahata, M., Reifenberger, G., Weller, M., Hänggi, D., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1905-0 · Cited by 313
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 312
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox132 · Cited by 307
Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas
Lu, C.-F., Hsu, F.-T., Hsieh, K. L.-C., Kao, Y.-C. J., Cheng, S.-J., Hsu, J. B.-K., Tsai, P.-H., Chen, R.-J., Huang, C.-C., Yen, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3445 · Cited by 306
European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma
Pace, A., Dirven, L., Koekkoek, J. A. F., Golla, H., Fleming, J., Rudà, R., Marosi, C., Rhun, E. L., Grant, R., Oliver, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30345-5 · Cited by 297
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2199 · Cited by 293
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
Kaloshi, G., Benouaich-Amiel, A., Diakite, F., Taillibert, S., Lejeune, J., Laigle-Donadey, F., Renard, M.-A., Iraqi, W., Idbaih, A., Paris, S., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000262034.26310.a2 · Cited by 286
Duffau, H. (2016) · Acta Neurochirurgica · doi:10.1007/s00701-015-2621-3 · Cited by 269
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Ellison, D. W., Hawkins, C., Jones, D. T. W., Onar-Thomas, A., Pfister, S. M., Reifenberger, G., & Louis, D. N. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01987-0 · Cited by 247
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
International Cancer Genome Consortium PedBrain Tumor Project (2016) · Nature Medicine · doi:10.1038/nm.4204 · Cited by 233
cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
Louis, D. N., Wesseling, P., Paulus, W., Giannini, C., Batchelor, T. T., Cairncross, J. G., Capper, D., Figarella-Branger, D., Lopes, M. B., Wick, W., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1808-0 · Cited by 229
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
Self-citationThe tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
Parker, B. C., Annala, M. J., Cogdell, D. E., Granberg, K. J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67144 · Cited by 215
Self-citationMGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Everhard, S., Kaloshi, G., Crinière, E., Benouaich‐Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang‐Xuan, K., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21044 · Cited by 215
Efficacy of anti-epileptic drugs in patients with gliomas and seizures
Breemen, M. S. M., Rijsman, R. M., Taphoorn, M. J. B., Walchenbach, R., Zwinkels, H., & Vecht, C. J. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5156-9 · Cited by 201
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198
Wiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Wang, Z., Zhang, C., Liu, X., Wang, Z., Sun, L., Li, G., Liang, J., Hu, H., Liu, Y., Zhang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196310 · Cited by 193
Self-citationReardon, D. A., Desjardins, A., Vredenburgh, J. J., O'Rourke, D. M., Tran, D. D., Fink, K. L., Nabors, L. B., Li, G., Bota, D. A., Lukas, R. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1140 · Cited by 187
Self-citationYang, P., Wang, Y., Peng, X., You, G., Zhang, W., Yan, W., Bao, Z., Wang, Y., Qiu, X., & Jiang, T. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1103-9 · Cited by 183
Self-citationBell, E. H., Zhang, P., Fisher, B. J., Macdonald, D. R., McElroy, J. P., Lesser, G. J., Fleming, J., Chakraborty, A. R., Liu, Z., Becker, A. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1977 · Cited by 182
Self-citationMolecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
Zacher, A., Kaulich, K., Stepanow, S., Wolter, M., Köhrer, K., Felsberg, J., Malzkorn, B., & Reifenberger, G. (2017) · Brain Pathology · doi:10.1111/bpa.12367 · Cited by 181
Clarke, J. L., Iwamoto, F. M., Sul, J., Panageas, K., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 179
Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 172
Kawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 166
Chinnaiyan, P., Won, M., Wen, P. Y., Rojiani, A. M., Werner‐Wasik, M., Shih, H. A., Ashby, L. S., Yu, H.-H. M., Stieber, V. W., Malone, S. C., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox209 · Cited by 164
Fisher, B. J., Hu, C., Macdonald, D. R., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner-Wasik, M., Bahary, J.-P., Liu, J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.012 · Cited by 163
Wick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Yan, W., Zhang, W., You, G., Bao, Z., Wang, Y., Liu, Y., Kang, C., You, Y., Wang, L., & Jiang, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030339 · Cited by 135
Self-citationPan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 131
Yang, P., Cai, J., Yan, W., Zhang, W., Wang, Y., Chen, B., Li, G., Li, S., Wu, C., Yao, K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now021 · Cited by 127
Self-citationAppay, R., Dehais, C., Colin, C., Alentorn, A., Carpentier, C., Ducray, F., Ibdaih, A., Kamoun, A., Mokhtari, K., Tabouret, E., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz126.000 · Cited by 126
Wijnenga, M. M. J., Dubbink, H. J., French, P. J., Synhaeve, N. E., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Dirven, C. M. F., Vincent, A. J. P. E., & van den Bent, M. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1781-z · Cited by 103
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Lee, Y., Koh, J., Kim, S., Won, J., Park, C., Choi, S. H., & Park, S. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0465-1 · Cited by 101
Chen, L., Voronovich, Z. A., Clark, K., Hands, I., Mannas, J., Walsh, M., Nikiforova, M. N., Durbin, E. B., Weiss, H. L., & Horbinski, C. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou097 · Cited by 88
Self-citationNovel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 86
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Kalpathy–Cramer, J., Chandra, V., Da, X., Ou, Y., Emblem, K. E., Muzikansky, A., Cai, X., Douw, L., Evans, J. G., Dietrich, J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2332-5 · Cited by 84
Cortical mapping by functional magnetic resonance imaging in patients with brain tumors
Majos, A., Tybor, K., Stefańczyk, L., & Goraj, B. M. (2004) · European Radiology · doi:10.1007/s00330-004-2565-0 · Cited by 78
Supratotal resection of diffuse gliomas – an overview of its multifaceted implications
Yordanova, Y. N., & Duffau, H. (2017) · Neurochirurgie · doi:10.1016/j.neuchi.2016.09.006 · Cited by 75
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions
Stefano, A. L. D., Pïcca, A., Saragoussi, É., Bielle, F., Ducray, F., Villa, C., Eoli, M., Paterra, R., Bellu, L., Mathon, B., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa121 · Cited by 74
Fujii, Y., Muragaki, Y., Maruyama, T., Nitta, M., Saito, T., Ikuta, S., Iseki, H., Hongo, K., & Kawamata, T. (2017) · Journal of neurosurgery · doi:10.3171/2017.3.jns162383 · Cited by 69
Zhang, C., Bao, Z., Wang, H., Yan, W., Liu, Y., Li, M., Zhang, W., Chen, L., & Jiang, T. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1519-9 · Cited by 68
Self-citationThe Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas
Patel, T., Bander, E. D., Venn, R. A., Powell, T. M., Cederquist, G., Schaefer, P. M., Puchi, L. A., Akhmerov, A., Ogilvie, S. Q., Reiner, A. S., et al. (2017) · Neurosurgery · doi:10.1093/neuros/nyx265 · Cited by 68
Talacchi, A., Turazzi, S., Locatelli, F., Sala, F., Beltramello, A., Alessandrini, F., Manganotti, P., Lanteri, P., Gambin, R., Ganau, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0193-x · Cited by 65
Bénit, C. P., & Vecht, C. J. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv038 · Cited by 64
Ding, X., Wang, Z., Chen, D., Wang, Y., Zhao, Z., Sun, C., Chen, D., Tang, C., Xiong, J., Chen, L., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2985-3 · Cited by 60
Self-citationWick, W., Roth, P. A., Wiestler, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2001 · Cited by 45
Xie, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0143 · Cited by 44
Spena, G., D’Agata, F., Panciani, P. P., Buglione, M., & Fontanella, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080916 · Cited by 42
Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours
Haque, F., Varlet, P., Puntonet, J., Storer, L. C. D., Bountali, A., Rahman, R., Grill, J., Carcaboso, A. M., Jones, C., Layfield, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0449-1 · Cited by 39
A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis
Koriyama, S., Nitta, M., Kobayashi, T., Muragaki, Y., Suzuki, A., Maruyama, T., Komori, T., Masui, K., Saito, T., Yasuda, T., et al. (2018) · Brain Tumor Pathology · doi:10.1007/s10014-018-0324-1 · Cited by 34
Updated Therapeutic Strategy for Adult Low-Grade Glioma Stratified by Resection and Tumor Subtype
Nitta, M., Muragaki, Y., Maruyama, T., Iseki, H., Ikuta, S., KONISHI, Y., Saito, T., Tamura, M., CHERNOV, M., Watanabe, A., et al. (2013) · Neurologia medico-chirurgica · doi:10.2176/nmc.53.447 · Cited by 32
Lizarazu, M., Robles, S. G., Pomposo, I., Nara, S., Amoruso, L., Quiñones, I., & Carreiras, M. (2020) · Brain and Language · doi:10.1016/j.bandl.2019.104741 · Cited by 30
Motor Cortical Network Plasticity in Patients With Recurrent Brain Tumors
Bulubas, L., Sardesh, N., Traut, T. I., Findlay, A. M., Mizuiri, D., Honma, S. M., Krieg, S. M., Berger, M. S., Nagarajan, S. S., & Tarapore, P. E. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.00118 · Cited by 28
Lassman, A. B., Pugh, S. L., Wang, T., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz175.064 · Cited by 25
Role of molecular biomarkers in glioma resection: a systematic review
Li, L., Wang, Y., Li, Y., Fang, S., & Jiang, T. (2020) · Chinese Neurosurgical Journal · doi:10.1186/s41016-020-00198-x · Cited by 24
Self-citationAwake craniotomy for gliomas involving motor-related areas: classification and function recovery
Fang, S., Li, Y., Wang, Y., Zhang, Z., & Jiang, T. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03520-w · Cited by 23
Self-citationIsocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
Li, M., Wang, Y., Cai, J., Zhang, C., Wang, K., Cheng, W., Liu, Y., Zhang, W., & Jiang, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130872 · Cited by 21
Self-citationThe impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma
Youland, R. S., Kreofsky, C. R., Schomas, D. A., Brown, P. D., Buckner, J. C., & Laack, N. N. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2599-1 · Cited by 19
A Novel Sequence: ZOOMit-Blood Oxygen Level-Dependent for Motor-Cortex Localization
Fang, S., Bai, H. X., Fan, X., Li, S., Zhang, Z., Jiang, T., & Wang, Y. (2019) · Neurosurgery · doi:10.1093/neuros/nyz441 · Cited by 13
Self-citationDong, C., Yuan, Z., Li, Q., & Wang, Y. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3407-1 · Cited by 12
Self-citationCAR-armed cell therapy for gliomas.
Zhai, Y., Li, G., Jiang, T., & Zhang, W. (2019) · PubMed · Cited by 9
Self-citation
Metadata
- Authors
- Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., Jiang, C., Yang, X., Kang, C., Qiu, X., Li, W., Li, S., Chen, L., Li, X., Liu, Z., Wang, W., Bai, H., Yao, Y., Li, S., Wu, A., Sai, K., Li, G., Yao, K., Wei, X., Liu, X., Zhang, Z., Dai, Y., Lv, S., Wang, L., Lin, Z., Dong, J., Xu, G., Ma, X., Zhang, W., Zhang, C., Chen, B., You, G., Wang, Y., Wang, Y., Bao, Z., Yang, P., Fan, X., Liu, X., Zhao, Z., Wang, Z., Li, Y., Wang, Z., Li, G., Fang, S., Li, L., Liu, Y., Liu, S., Shan, X., Liu, Y., Chai, R., Hu, H., Chen, J., Yan, W., Cai, J., Wang, H., Chen, L., Yang, Y., Wang, Y., Han, L., & Wang, Q.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 499
- Pages
- 60-72
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W4211260562
- Cited by
- 431
- References
- 121
- FWCI
- 28.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.